{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05521997",
            "orgStudyIdInfo": {
                "id": "202301163"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01CA181745",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01CA181745"
                }
            ],
            "organization": {
                "fullName": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer",
            "officialTitle": "Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "glutaminase-inhibition-and-chemoradiation-in-advanced-cervical-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08-31",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2030-11-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-11-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-26",
            "studyFirstSubmitQcDate": "2022-08-26",
            "studyFirstPostDateStruct": {
                "date": "2022-08-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Washington University School of Medicine",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                },
                {
                    "name": "Calithera Biosciences, Inc",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Cervical Carcinoma",
                "Cervical Cancer",
                "Cervix Cancer",
                "Cancer of the Cervix"
            ],
            "keywords": [
                "advanced cervical cancer",
                "Glutaminase Inhibitor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Randomization will occur on a 5:1 basis to experimental arm and control arm. The first 5 participants randomized to the experimental arm will be considered the safety lead-in.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 42,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Control Arm: Standard of Care Chemoradiation",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "-Participants will receive 7 weeks of standard of care chemoradiation.",
                    "interventionNames": [
                        "Radiation: Radiation treatment",
                        "Drug: Cisplatin"
                    ]
                },
                {
                    "label": "Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation",
                    "type": "EXPERIMENTAL",
                    "description": "-Participants will receive 2 weeks of telaglenastat and 7 weeks of standard of care chemoradiation plus telaglenastat.",
                    "interventionNames": [
                        "Drug: Telaglenastat",
                        "Radiation: Radiation treatment",
                        "Drug: Cisplatin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Telaglenastat",
                    "description": "-800 mg twice per day by mouth",
                    "armGroupLabels": [
                        "Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation"
                    ],
                    "otherNames": [
                        "CB-893"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Radiation treatment",
                    "description": "* Standard of care\n* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.",
                    "armGroupLabels": [
                        "Control Arm: Standard of Care Chemoradiation",
                        "Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cisplatin",
                    "description": "* Standard of care\n* Weekly administration of cisplain",
                    "armGroupLabels": [
                        "Control Arm: Standard of Care Chemoradiation",
                        "Experimental Arm #1: Telaglenastat + Standard of Care Chemoradiation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression-free survival (PFS) - experimental arm only",
                    "description": "* PFS is defined as the duration of time from start of telaglenastat to time of progression or death, whichever occurs first.\n* Progressive disease: New foci of abnormal FDG uptake not present on the pretreatment FDG-PET study",
                    "timeFrame": "Through completion of follow-up (estimated to be 24 months and 9 weeks)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Acute toxicity as measured by number of acute adverse events experienced by participant - experimental arm only",
                    "description": "* Toxicity evaluation will report events according to Common Terminology Criteria for Adverse Events v5.0 (CTCAE)\n* Acute toxicity is defined as any toxicity occurring within 90 days from first receiving study radiotherapy or death, whatever event is observed first.",
                    "timeFrame": "From start of chemoradiation treatment through 90 days"
                },
                {
                    "measure": "Late toxicity as measured by number of late adverse events experienced by participant - experimental arm only",
                    "description": "* Toxicity evaluation will report events according to Common Terminology Criteria for Adverse Events v5.0 (CTCAE)\n* Late toxicities include any toxicity that is determined possibly, probably, or definitely related to treatment, within 24 months after completion of treatment.",
                    "timeFrame": "From day 91 through 24 months after completion of chemoradiation"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "-OS is defined as the days from the start of Telaglenastat treatment to the date of death, censored at the last follow-up otherwise.",
                    "timeFrame": "Through completion of follow-up (estimated to be 24 months and 9 weeks)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nPatients eligible for definitive chemoradiotherapy, including brachytherapy\n\n* Patient age \u2265 18 years.\n* Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous, adenosquamous, adenocarcinoma or poorly differentiated); Federation of Gynecology and Obstetrics (FIGO) 2018 clinical stages III-IVA.\n* Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n* Absolute neutrophil count \u2265 1,500/mcL.\n* Platelets \u2265 100,000/mcL.\n* Hemoglobin \u2265 8 g/dL (can be transfused prior to study).\n* Total bilirubin \u2264 1.5 x institutional upper limit of normal (ULN); patients with known Gilbert disease with serum bilirubin \u2264 3 x ULN may be enrolled.\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]/alanine aminotransfersase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\] \u2264 2.5 x ULN.\n* Alkaline phosphatase \u2264 2.5 x ULN.\n* Serum creatinine \u2264 1.5 mg/dL to receive weekly cisplatin; patients whose serum creatinine is between 1.5 and 1.9 mg/dL are eligible for cisplatin if there is no hydronephrosis and the estimated creatinine clearance (CCr) is \u2265 30 ml/min. For the purpose of estimating the CCr, formulas, including Cockcroft and Gault for females or similar, should be used.\n* International normalize ratio (INR) and activated partial thromboplastin time (aPTT) \u2264 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular weight heparin or warfarin, should be on a stable dose).\n* Patient does not have uncontrolled diabetes mellitus (i.e. fasting blood glucose \\>200 mg/dL).\n* Patient does not have a known allergy to cisplatin or compounds of similar biologic composition as CB-839.\n* Patient is not actively breastfeeding (or has agreed to discontinue before the initiation of protocol therapy).\n* Ability to understand and the willingness to sign a written informed consent document.\n* Patients does not have known human immunodeficiency virus syndrome (HIV testing optional).\n\nExclusion Criteria:\n\n* Patient has another concurrent active invasive malignancy.\n* Patient has received prior radiation therapy to the pelvis or previous therapy of any kind for this malignancy, or pelvic radiation for any prior malignancy.\n* Patient is receiving another investigational agent for the treatment of cancer.\n* Poorly controlled diabetes, with inability to perform 18F-FDG PET scan.\n* Patient is pregnant or breastfeeding.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Mean resting QTc \\> 470 msec obtained by electrocardiogram (ECG).\n* Severe, active co-morbidity defined as follows:\n\n  * Current (within 28 days of cycle 1, day 1) signs and/or symptoms of bowel obstruction\n  * Patients who require parental hydration and/or nutrition\n  * Patients who require drainage gastrostomy tube\n  * Evidence of bleeding diathesis or clinically significant coagulopathy\n  * Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture\n  * History of hemoptysis (\\>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment\n  * Significant cardiovascular or cerebrovascular disease including: Uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\>= 150; diastolic blood pressure \\[DBP\\] \\>= 90)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Julie K Schwarz, M.D., Ph.D.",
                    "role": "CONTACT",
                    "phone": "314-608-6813",
                    "email": "jschwarz@wustl.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Julie K Schwarz, M.D., Ph.D.",
                    "affiliation": "Washington University School of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Washington University School of Medicine",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Julie K Schwarz, M.D., Ph.D.",
                            "role": "CONTACT",
                            "phone": "314-608-6813",
                            "email": "jschwarz@wustl.edu"
                        },
                        {
                            "name": "Julie K Schwarz, M.D., Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Stephanie Markovina, M.D., Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Andrea Hagemann, M.D., MSCI",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Dineo Khabele, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Lindsay Kuroki, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "L. Stewart Massad, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Carolyn McCourt, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Maggie Mullen, M.S.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "David Mutch, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Matthew Powell, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Premal Thaker, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "David DeNardo, Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Gary Patti, Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Li Ding, Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Esther Lu, Ph.D.",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine",
                    "url": "http://www.siteman.wustl.edu"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002583",
                    "term": "Uterine Cervical Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000002577",
                    "term": "Uterine Cervical Diseases"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "asFound": "Cervical Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5825",
                    "name": "Uterine Cervical Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002945",
                    "term": "Cisplatin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "asFound": "Children",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}